In 2016, new highly active treatment options for relapsing–remitting multiple sclerosis (MS) emerged. At the same time, large clinical trials in progressive MS highlighted the limitations of immune-directed therapies, and called for new strategies to treat disease progression in MS.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Alping, P. et al. Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann. Neurol. 79, 950–958 (2016).
Hauser, S. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1601277 (2016).
Atkins, H. L. et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet 388, 576–585 (2016).
Lublin, F. et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387, 1075–1084 (2016).
Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1606468 (2016).
Steiner, D. et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial. BioGenConferences http://biogenconferences.com/AAN2016/Tysabri/TYS_Steiner_ASCEND_SPMS_Primary_data.pdf (2016).
Jürgens, T. et al. Reconstruction of single cortical projection neurons reveals primary spine loss in multiple sclerosis. Brain 139, 39–46 (2016).
Cortese, M. et al. Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom. Ann. Neurol. 80, 616–624 (2016).
Kantarci, O. H. et al. Primary progressive multiple sclerosis evolving from radiologically isolated syndrome. Ann. Neurol. 79, 288–294 (2016).
Confavreux, C. & Vukusic, S. Natural history of multiple sclerosis: a unifying concept. Brain 129, 606–616 (2006).
B.H. and M.M. were supported by the German Competence Network Multiple Sclerosis' (German Ministry for Research and Education). B.H. was supported by the Transregional Collaborative Research Center (CRC) SFB TR-128, and M.M. by the Hertie Foundation.
B.H. has served on scientific advisory boards for Novartis, Bayer Schering, F. Hoffmann-La Roche, AllergyCare and Genentech. He has received honoraria for lectures from Teva Pharmaceutical Industries, Biogen Idec, Medimmune, Merck Serono and F. Hoffmann-La Roche, and has received research support from Chugai Pharmaceuticals and F. Hoffmann-La Roche. He has filed two patents, one for the detection of antibodies and T cells against KIR4.1 in a subpopulation of multiple sclerosis patients, and one for genetic determinants of neutralizing antibodies to IFNβ. M.M. has received research support from Merck Serono and Novartis.
About this article
Cite this article
Hemmer, B., Mühlau, M. Immune-directed therapies in MS — efficacy and limitations. Nat Rev Neurol 13, 72–74 (2017). https://doi.org/10.1038/nrneurol.2017.2
This article is cited by
Nature Reviews Immunology (2022)